ESR1 and triple-negative breast carcinoma: Approximately 15-25% of all BC cases lack the biomarkers human epidermal growth factor receptor 2 (HER2), estrogen receptor (ER), and progesterone receptor (PR), classifying them as triple-negative breast cancer (TNBC).